91˿Ƶ

Event

Near-Equivalent Q-learning Policies for Dynamic Treatment Regimes / Trends in the Prescription of Central Nervous System Depressants in Patients with Chronic Obstructive Pulmonary Disease in the United Kingdom Primary Care, 2000 – 2022

Wednesday, February 18, 2026 15:30to16:30

Sophia Yazzourh, PhD
Postdoctoral Fellow
Department of Epidemiology, Biostatistics and Occupational Health | 91˿Ƶ

Omotayo Olayoe

PhD Candidate in Epidemiology | Vanier Scholar

Department of Epidemiology, Biostatistics and Occupational Health | 91˿Ƶ

WHEN: Wednesday, February 18, 2026, from 3:30 to 4:30 p.m.
WHERE: Hybrid | 2001 91˿Ƶ College Avenue, Rm 1140;
NOTE: Sophia Yazzourh and Omotayo Olayoe will be presenting in-person at SPGH 

Abstracts

Near-Equivalent Q-learning Policies for Dynamic Treatment Regimes

Precision medicine seeks to adapt treatments to individual patient profiles in order to deliver the right treatment to the right patient at the right time, particularly in longitudinal settings with multiple decision points. Dynamic Treatment Regimes provide a formal framework to model treatment as a sequence of adaptive decisions evolving with the patient’s clinical trajectory. In this talk, we focus on Near-Equivalent Q-learning Policies, an extension of standard Q-learning that moves beyond the identification of a single “optimal” strategy. Instead, the method characterizes a set of statistically near-optimal treatment policies that achieve comparable expected outcomes. This allows treatment decisions to remain data-driven while supporting clinically flexible strategies, where multiple valid options can coexist and be adapted to practical constraints.

Trends in the Prescription of Central Nervous System Depressants in Patients with Chronic Obstructive Pulmonary Disease in the United Kingdom Primary Care, 2000 – 2022

Prescribing patterns of central nervous system (CNS) depressants have evolved in recent years, but trends in patients with chronic obstructive pulmonary disease (COPD) remain unknown. Assessing these trends is essential given the potential risk of respiratory depression and other adverse respiratory events in this population. Thus, we examined time trends in the prescription of CNS depressants among patients with COPD in UK primary care from 2000 to 2022.

Speaker Bios

Sophia Yazzourh: For more information please visit:

Omotayo Olaoye: For more information, please visit:

Back to top